Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration.
As of February, a great deal of uncertainty still remains as firms—and the stock market—try to predict the Trump administration's next moves. There is a lot on the table right now that could work for—or against—life sciences companies, specifically pharmaceuticals.
What does the future hold for pharmaceuticals under President Trump?
This is the billion dollar question that no one really knows the answer to. The president hasn't announced anything yet but based on what we do know, changes could be good for the pharmaceutical industry, bad, or leave things mostly unchanged.
Here's a quick summary:
- President Trump was not as outspoken about his plans to reduce prescription prices as Mrs. Clinton was but he has remarked that something needs to be done about the prices of medications